NON-HODGKIN LYMPHOMA

This early-phase study tests an oral drug called AS-1763 in 120 adults with certain blood cancers (CLL/SLL or NHL) that have not responded to at least two prior treatments. The main goals are to find the safest dose and see how well the drug shrinks tumors. Participants take the …

This early-stage study tests a new type of stem cell transplant for children whose blood cancers or solid tumors have returned or are hard to treat. Doctors use a special method to remove certain immune cells from the donor's stem cells and give a drug called zoledronate after tr…

This study tests a new treatment called ronde-cel for people with aggressive B-cell lymphoma that has come back or not responded to at least two prior therapies. Ronde-cel is made from the patient's own immune cells, which are reprogrammed to target two markers on cancer cells (C…

This early-stage study tests a new drug called KSV01 in 18 people with a type of blood cancer (diffuse large B-cell lymphoma) that has come back or not responded to standard treatments. The main goal is to check if the injection is safe and tolerable, and to see if it can help co…

This study is testing whether a cord blood transplant can help children and young adults (up to age 26) with blood cancers like leukemia and lymphoma. The treatment uses donated cord blood to replace damaged bone marrow. The main goal is to see how many patients remain cancer-fre…

This early-phase trial tests azer-cel, a ready-made CAR T cell therapy, in adults with relapsed or refractory non-Hodgkin lymphoma, B-cell acute lymphoblastic leukemia, and related blood cancers. The goal is to see if the treatment is safe and can shrink or control tumors. About …

This study tests a new drug called epcoritamab combined with other cancer medicines in adults with Non-Hodgkin lymphoma, a type of blood cancer. About 496 participants will receive different drug combinations to see which are safe and work best. The goal is to find better treatme…

This study tests a two-step stem cell transplant using lower doses of radiation and chemo before the transplant. The goal is to reduce deaths from the transplant itself while still treating blood cancers like leukemia and lymphoma. About 63 adults will take part. If successful, t…

This study tests whether giving a targeted radiation drug before standard CAR-T cell therapy can improve outcomes for people with relapsed or refractory diffuse large B-cell lymphoma. About 30 adults will receive the radiation drug followed by CAR-T cells. The goal is to see if t…

This early-phase trial tests whether adding the drug pomalidomide to standard chemotherapy (with or without rituximab) is safe and effective for people with HIV who have certain types of non-Hodgkin lymphoma. About 25 adults with high-risk features will receive up to 6 cycles of …

This study tests a stem cell transplant using a patient's own cells to treat Hodgkin and non-Hodgkin lymphoma. It includes people with HIV. The goal is to see if a radiation-free preparation improves survival at 3 years compared to older methods. About 150 participants will be en…

This early-phase study tests a new treatment for adults with B-cell lymphomas that have come back or not responded to standard therapies. The treatment combines LV20.19 CAR T-cells (a type of immune cell therapy) with a targeted drug called pirtobrutinib. The goal is to see if th…

This study tests whether Darzalex Faspro can safely lower donor-specific antibodies (DSAs) in patients at high risk of rejecting a stem cell transplant. About 8 adults with blood cancers or bone marrow failure will receive the drug before standard transplant preparation. The goal…

This early-stage study tests a new gene therapy called VNX-101 in about 32 people with blood cancers (like certain leukemias and lymphomas) that have returned or not responded to standard treatments. The therapy aims to help the body's immune system attack cancer cells that have …

This program provides early access to AVM0703, a drug that helps the immune system fight cancer, for patients with various solid tumors or blood cancers. It is available to eligible patients in the US upon request by a licensed doctor. Side effects are generally mild, such as itc…

This study tests whether adding XEMBIFY (an antibody replacement) to standard treatment can reduce serious bacterial infections in adults with certain blood cancers (chronic lymphocytic leukemia, multiple myeloma, or non-Hodgkin lymphoma) who have low antibody levels and frequent…

This early-phase trial tests a new type of immune cell therapy (TmCD19-IL18 CAR T cells) in about 24 people with relapsed or refractory CD19+ non-Hodgkin lymphoma. The main goals are to find a safe dose and check for side effects. Researchers will also watch for signs that the tr…

This early-phase study is testing whether a second infusion of the CAR T-cell therapy Axi-Cel is safe for people with aggressive non-Hodgkin lymphoma who are at high risk of their cancer returning after standard CAR T treatment. About 20 adults will receive the extra dose and be …

This early-phase study tests a new type of immune cell therapy (CAR T cells) that targets two proteins, CD79b and CD19, on lymphoma cells. It is for people with non-Hodgkin lymphoma whose cancer has returned or stopped responding to standard treatments. The main goals are to chec…

This study tests a new drug called CHO-H01, alone or combined with lenalidomide, in adults with a type of blood cancer called Non-Hodgkin lymphoma that has returned or not responded to prior therapy. The first part finds the safest dose, and the second part checks how well the co…

This study tests a combination of five drugs (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, called ViPOR) in adults with B-cell lymphoma that has come back or not responded to prior treatment. The main goal is to check the safety of this drug mix. Up to 155 p…

This study tests a new treatment called CTX112 for people with B-cell blood cancers (like lymphoma or leukemia) that have not responded to standard therapy or have returned. CTX112 uses CRISPR gene-editing to create donor T-cells that can target and kill cancer cells. The trial w…

This study tests a new approach to collecting stem cells for people with multiple myeloma, Hodgkin lymphoma, or non-Hodgkin lymphoma who need a stem cell transplant. The goal is to see if using a standard drug alone, and adding another drug only when needed, can collect enough st…

This study gives patients with blood cancers, immune disorders, and other serious conditions access to unlicensed cord blood units for transplantation. The goal is to see how well the body rebuilds its infection-fighting cells after the transplant. Children and adults of any age …

This early-stage study tests a new drug called AXT-1003 in 78 people with advanced non-Hodgkin lymphoma or solid tumors that have not responded to standard treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look at whether the d…

This early-stage trial tests a new drug called CC312 for people with certain blood cancers (like lymphoma or leukemia) that have returned or stopped responding to standard treatments. The main goals are to check the drug's safety and find the right dose. About 44 adults will take…

This study tests a new treatment for people with CD30-positive lymphomas (like Hodgkin lymphoma) that have come back or not responded to standard therapy. The treatment uses immune cells from healthy donors that are modified to better target and kill cancer cells, plus a safety s…

This early-phase study tests a new treatment called GB5005 for adults with a type of blood cancer (B-cell non-Hodgkin lymphoma) that has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and…

This study compares two approaches to prevent graft-versus-host disease (GVHD) in 400 people receiving stem cell transplants from unrelated donors for blood cancers like leukemia and lymphoma. One method uses a drug called thymoglobulin, while the other uses a combination of calc…

This study tests whether adding the drug ibrutinib to standard chemotherapy can better control primary central nervous system lymphoma (PCNSL) in people who are not eligible for a stem cell transplant. About 30 adults with newly diagnosed PCNSL will receive the combination therap…

This study tests a new treatment for people with advanced B-cell lymphoma or leukemia that has returned or not responded to standard therapy. Researchers take a patient's own T-cells, add a special receptor (CAR) that targets the CD19 protein on cancer cells, and also add extra s…

This study tests whether adding a JAK inhibitor (ruxolitinib) to an immunotherapy drug (pembrolizumab) is safe and effective for people with certain types of lymphoma that have come back or not responded to treatment. About 53 adults with Hodgkin or non-Hodgkin lymphoma will take…

This early-phase study tests a new drug called SB-4826 in adults with advanced solid tumors or non-Hodgkin lymphoma. The main goal is to find a safe dose and see if the drug shrinks tumors. Some participants with lymphoma will also receive the drug combined with rituximab. The st…

This study tests a new drug called CCS1477 in people with advanced blood cancers like leukemia, lymphoma, and multiple myeloma. The goal is to see if the drug is safe and helps shrink tumors. About 250 adults who have already tried standard treatments will take part.

This study tests an experimental drug called AZD3470 in people with certain blood cancers like lymphoma. The drug is taken as a pill, either alone or with other cancer treatments. The main goals are to check safety and find the best dose. About 161 adults and teens will take part…

This early-phase study tests a new drug called SGR-1505 in about 98 adults with various B-cell blood cancers (like lymphomas and leukemia). The main goals are to find the safest dose and understand side effects. Participants will receive the drug alone, and researchers will monit…

This study tests a new mix of drugs (linperlisib plus CPT) in 180 adults with Non-Hodgkin lymphoma that returned or didn't respond to prior therapy. The goal is to see how many patients have their tumors shrink or disappear. This is a Phase 2 trial, meaning it's still early, and …

This study tests a combination of three drugs (epcoritamab, zanubrutinib, and rituximab) in 45 people with follicular or marginal zone lymphoma that has come back or not responded to prior treatment. The goal is to see how well the combo shrinks tumors and controls the disease. P…

This early study tests a new treatment called LV009 in 10 adults with certain blood cancers (non-Hodgkin lymphoma or acute lymphoblastic leukemia) that have returned or not responded to standard therapy. The main goal is to check if the treatment is safe. Participants receive the…

This study tests an experimental pill called LP-118 in up to 100 adults with blood cancers that have come back or not responded to treatment. The main goal is to find a safe dose and see how the body processes the drug. Early signs of effectiveness will also be tracked, but this …

This early-phase study tests a personalized cell therapy for people with Non-Hodgkin lymphoma that has come back or not responded to standard treatments. Participants receive their own immune cells that have been genetically modified to recognize and attack cancer cells. The main…

This study tests a new drug, BGB-16673, that destroys a protein cancer cells need to survive. It is for people with certain blood cancers (like lymphoma or leukemia) that have come back or not responded to other treatments. The goal is to find the best dose and see if it shrinks …

This study looks at the long-term safety of the drug pirtobrutinib in people with chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma (NHL) who were already in an earlier trial. About 279 participants will continue their treatment or follow-up visits. The main goal is to t…

This study tests whether combining two drugs, pirtobrutinib and venetoclax, can control mantle cell lymphoma (MCL) that has come back or not responded to prior therapy. About 30 adults with confirmed MCL will take both pills by mouth. The goal is to see how many patients respond …

This study looks at the long-term safety of the drug pirtobrutinib in people with chronic lymphocytic leukemia or non-Hodgkin lymphoma. About 787 adults who already took part in earlier pirtobrutinib studies can join. They will keep getting the drug or have follow-up visits to mo…

This study tests a new treatment using donor immune cells (CAR-NK cells) that are specially designed to attack cancer. The target on the cancer cells is chosen by analyzing a tumor sample or a blood test. The goal is to see if this approach is safe and can shrink or control advan…

This early-phase trial tests a new type of immune cell therapy (CD19x22 CAR T) in teens and adults with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The therapy uses a patient's own immune cells, modified to attack two targets on cancer cells. The…

This study tests a special cord blood transplant for people with high-risk blood cancers like leukemia and lymphoma. Participants get chemotherapy and radiation before the transplant to kill cancer cells, then donor stem cells to rebuild healthy blood. After transplant, drugs are…

This study tests a new form of the chemotherapy drug carmustine (called VI-0609) that doesn't contain ethanol, compared to the standard version (BiCNU) which does. About 49 adults with Hodgkin or non-Hodgkin lymphoma who are getting a stem cell transplant will take part. The goal…

This study tests a new drug called BGB-16673 in people with several types of B-cell blood cancers (like lymphoma and leukemia) that have come back or not responded to other treatments. The trial has two parts: first, finding the safest dose, and then testing how well that dose sh…

This early-stage study tests two experimental drug combinations in adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments. The main goals are to check safety and find the best dose, while also measuring how well the drugs shri…

This study tests a new treatment called ronde-cel for people with a fast-growing blood cancer (large B-cell lymphoma) that has come back or not responded to first treatment. Ronde-cel is a personalized cell therapy that targets two markers on cancer cells (CD19 and CD20), aiming …

This early-stage study tests a new treatment called PIC1 injection for adults with relapsed or refractory B-cell Non-Hodgkin lymphoma, a type of blood cancer that has not responded to standard therapies. The main goal is to check the safety of the injection and see how many patie…

This study tests a vaccine (CMV-MVA Triplex) given to stem cell donors to boost their immunity against cytomegalovirus (CMV). When the donor's stem cells are transplanted into the patient, that immunity is passed along, potentially preventing CMV infection. The trial involves 216…

This early-phase trial tests a vaccine (CMV-MVA Triplex) given to both stem cell donors and recipients to boost immunity against cytomegalovirus (CMV) and prevent active infection after transplant. About 46 people with various blood cancers or disorders will take part. The goal i…

This study looks at whether a Mediterranean diet and exercise program can help lymphoma patients finish their chemotherapy with fewer side effects. About 140 adults with untreated Hodgkin or Non-Hodgkin lymphoma will take part. Researchers will measure how many patients join, com…

This study tests whether a tailored physical activity program helps lymphoma and breast cancer patients preserve their exercise capacity, heart function, memory, and quality of life during treatment. About 110 adults aged 18-85 will be randomly assigned to either health education…

This study tests a new PET imaging tracer that lights up active immune cells attacking lymphoma tumors after CAR-T therapy. About 32 adults with relapsed or hard-to-treat non-Hodgkin lymphoma will receive the tracer and a PET scan. The goal is to see if the scan can predict which…

This study looks at whether firefighters' exposure to dangerous chemicals on the job raises their risk of developing blood cancers. Researchers will test blood samples from 300 firefighters aged 40-49 with at least 5 years of service to look for early signs of pre-cancerous chang…

This study is testing whether an artificial intelligence (AI) tool can help match cancer patients with clinical trials they might be eligible for. Researchers will enroll up to 50,000 people with various types of cancer to see if the AI increases trial enrollment and to identify …

This study is tracking 2000 adults with newly diagnosed breast, colorectal, lung, melanoma, or lymphoma cancer who are getting chemotherapy or immunotherapy. Researchers want to see if using cannabis or cannabinoids helps with symptoms like pain, nausea, or fatigue, and whether i…

This study aims to discover new genes that may cause cancer to run in families. Researchers will collect blood, health information, and leftover tumor samples from 1,500 people with a family history of childhood cancer. The goal is to build a registry and sample bank to help futu…

This study talks with Spanish-speaking families who have a child with leukemia or lymphoma to learn about their experiences and any language barriers. The goal is to find ways to improve communication and make the cancer center more welcoming and helpful for these families. About…

This early-phase study is testing a new imaging agent called [68Ga]-pentixafor to see how well it lights up certain blood and solid tumors on PET/CT scans. About 30 people with non-Hodgkin lymphoma, multiple myeloma, or rare histiocytic disorders will receive the agent and then h…

This study looks at whether peer-to-peer education and support can help more adolescents and young adults (ages 15-39) living with HIV in Zambia get screened for cancer early and stick with their cancer treatment. About 4,100 participants will take part. The goal is to reduce can…

This study is testing whether daily voice recordings made on a smartphone can help doctors spot early signs of a brain-related side effect called ICANS in people receiving CAR T-cell therapy for lymphoma or multiple myeloma. Researchers will ask 20 participants to record their vo…

This study looks at how social and genetic factors impact the long-term health of adolescent and young adult survivors of Hodgkin or non-Hodgkin lymphoma. Researchers will collect blood samples and health information from 2,000 survivors to understand why some face more health pr…

This study looks at tumor samples from 50 people who developed a second cancer after receiving a BMS gene-modified cell therapy (like CAR-T). Researchers will test whether the therapy's genes are present in the new tumor. The goal is to understand if the treatment played a role, …

This study looks at how the body handles venetoclax when the tablet is crushed and mixed into a liquid for children and young adults with blood cancers like leukemia or lymphoma. It includes 30 people under 39 who already need a central line for blood draws. The goal is to find o…

This study looks at how social connections and physical activity influence the quality of life of young adults who have had cancer. Researchers will follow 250 survivors over time to track changes in their relationships, exercise habits, and overall well-being. The goal is to fin…

This study looks at how the body's ability to break down certain drugs changes in young people (ages 6-25) with Hodgkin or non-Hodgkin lymphoma. Researchers will give small doses of probe drugs during regular hospital visits and take blood samples to measure metabolism. The goal …

This study looks at whether a tailored exercise program can slow down the aging process in people aged 50 and older who have survived blood cancers like leukemia or lymphoma. Researchers want to find out how much and what type of exercise is needed to make a difference. The goal …